A functional polymorphism at miR‑491‑5p binding site in the 3'UTR of MMP9 gene confers increased risk for pressure ulcers after hip fracture

Yang,Rui; Han,Li; Zeng,Xiantie

doi:10.3892/or.2018.6338

A functional polymorphism at miR‑491‑5p binding site in the 3'UTR of MMP9 gene confers increased risk for pressure ulcers after hip fracture

Authors:
- Rui Yang
- Li Han
- Xiantie Zeng
View Affiliations

Affiliations: Department of Traumatic Ankle Surgery, Tianjin Hospital, Tianjin 300211, P.R. China
Published online on: March 28, 2018 https://doi.org/10.3892/or.2018.6338
Pages: 2695-2702

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The roles of matrix metalloproteinase (MMP)9 in the control of pressure ulcers (PU) after hip fracture as well as how the rs1056629 in MMP9 3'UTR compromises the interaction between MMP9 and miR‑491 were explored. Online miRNA database (http://www.bioguo.org) was utilized to explore gene polymorphism in MMP9 3'UTR that might break the interaction between MMP9 and miRNA. Luciferase assay was utilized to confirm the miRNA targeted MMP9. Real‑time PCR, western blot analysis and immunohistochemistry were carried out to understand the roles of MMP9 in PU as well as how rs1056629 in MMP9 3'UTR compromises the interaction between MMP9 and miR‑491. rs1056629 in MMP9 3'UTR that compromised the interaction between MMP9 and four miRNAs including miR‑194‑3p, miR‑491, miR‑1915‑3p and miR‑941, and only miR‑491 among miR‑194‑3p, miR‑491, miR‑1915‑3p and miR‑941 decreased luciferase activity of wild‑type MMP9 3'UTR, and luciferase activities of mutant‑3 and mutant‑4 MMP9 3'UTR in miR‑491 overexpressing cells was comparable with scramble control. miR‑194‑3p, miR‑491, miR‑1915‑3p and miR‑941 levels in PU group was comparable with healthy control, and miR‑194‑3p, miR‑491, miR‑1915‑3p and miR‑941 in subjects carrying AA genotype was similar with those in AC and CC groups. MMP9 mRNA and protein, and histology score in subjects with PU were much higher, and were also much higher in AA group. Only miR‑491 mimic among miR‑194‑3p, miR‑491, miR‑1915‑3p and miR‑941 mimics downregulated the MMP9 level, and only miR‑491 inhibitor among miR‑194‑3p, miR‑491, miR‑1915‑3p and miR‑941 inhibitors upregulated the MMP9 level. Our study indicated that rs1056629 polymorphism could be a novel biomarker for predicting the occurrence of PU after a hip fracture.

View Figures

View References

1	Bours GJ, Halfens RJ, Abu-Saad HH and Grol RT: Prevalence, prevention, and treatment of pressure ulcers: Descriptive study in 89 institutions in the Netherlands. Res Nurs Health. 25:99–110. 2002. View Article : Google Scholar : PubMed/NCBI
2	Veronesi G, Harley K, Dugdale P and Short SD: Governance, transparency and alignment in the Council of Australian Governments (COAG) 2011 national health reform agreement. Aust Health Rev. 38:288–294. 2014. View Article : Google Scholar : PubMed/NCBI
3	Black J, Baharestani M, Cuddigan J, Dorner B, Edsberg L, Langemo D, Posthauer ME, Ratliff C and Taler G: National Pressure Ulcer Advisory Panel: National pressure ulcer advisory panel's updated pressure ulcer staging system. Dermatol Nurs. 19:343–349; quiz 350. 2007.PubMed/NCBI
4	Thompson D: A critical review of the literature on pressure ulcer aetiology. J Wound Care. 14:87–90. 2005. View Article : Google Scholar : PubMed/NCBI
5	Baumgarten M, Margolis DJ, Orwig DL, Shardell MD, Hawkes WG, Langenberg P, Palmer MH, Jones PS, McArdle PF, Sterling R, et al: Pressure ulcers in elderly patients with hip fracture across the continuum of care. J Am Geriatr Soc. 57:863–870. 2009. View Article : Google Scholar : PubMed/NCBI
6	Lindholm C, Sterner E, Romanelli M, Pina E, Torra y Bou J, Hietanen H, Iivanainen A, Gunningberg L, Hommel A, Klang B and Dealey C: Hip fracture and pressure ulcers-the Pan-European Pressure Ulcer Study-intrinsic and extrinsic risk factors. Int Wound J. 5:315–328. 2008. View Article : Google Scholar : PubMed/NCBI
7	Ladwig GP, Robson MC, Liu R, Kuhn MA, Muir DF and Schultz GS: Ratios of activated matrix metalloproteinase-9 to tissue inhibitor of matrix metalloproteinase-1 in wound fluids are inversely correlated with healing of pressure ulcers. Wound Repair Regen. 10:26–37. 2002. View Article : Google Scholar : PubMed/NCBI
8	Bonaldo P and Sandri M: Cellular and molecular mechanisms of muscle atrophy. Dis Model Mech. 6:25–39. 2013. View Article : Google Scholar : PubMed/NCBI
9	Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM: Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
10	Lewis BP, Burge CB and Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 120:15–20. 2005. View Article : Google Scholar : PubMed/NCBI
11	Deveci M, Catalyürek UV and Toland AE: mrSNP: Software to detect SNP effects on microRNA binding. BMC Bioinformatics. 15:732014. View Article : Google Scholar : PubMed/NCBI
12	Yuan M, Zhan Q, Duan X, Song B, Zeng S, Chen X, Yang Q and Xia J: A functional polymorphism at miR-491-5p binding site in the 3′-UTR of MMP-9 gene confers increased risk for atherosclerotic cerebral infarction in a Chinese population. Atherosclerosis. 226:447–452. 2013. View Article : Google Scholar : PubMed/NCBI
13	Gumieiro DN, Rafacho BP, Gonçalves AF, Santos PP, Azevedo PS, Zornoff LA, Pereira GJ, Matsubara LS, Paiva SA and Minicucci MF: Serum metalloproteinases 2 and 9 as predictors of gait status, pressure ulcer and mortality after hip fracture. PLoS One. 8:e574242013. View Article : Google Scholar : PubMed/NCBI
14	Zhao XL, Luo X, Wang ZX, Yang GL, Liu JZ, Liu YQ, Li M, Chen M, Xia YM, Liu JJ, et al: Local blockage of EMMPRIN impedes pressure ulcers healing in a rat model. Int J Clin Exp Pathol. 8:6692–6699. 2015.PubMed/NCBI
15	Chen W and Qiu Y: Ginsenoside Rh2 targets EGFR by up-regulation of miR-491 to enhance anti-tumor activity in hepatitis B virus-related hepatocellular carcinoma. Cell Biochem Biophys. 72:325–331. 2015. View Article : Google Scholar : PubMed/NCBI
16	Li X, Liu Y, Granberg KJ, Wang Q, Moore LM, Ji P, Gumin J, Sulman EP, Calin GA, Haapasalo H, et al: Two mature products of MIR-491 coordinate to suppress key cancer hallmarks in glioblastoma. Oncogene. 34:1619–1628. 2015. View Article : Google Scholar : PubMed/NCBI
17	Nakano H, Miyazawa T, Kinoshita K, Yamada Y and Yoshida T: Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer. 127:1072–1080. 2010. View Article : Google Scholar : PubMed/NCBI
18	Leivonen SK, Sahlberg KK, Mäkelä R, Due EU, Kallioniemi O, Børresen-Dale AL and Perälä M: High-throughput screens identify microRNAs essential for HER2 positive breast cancer cell growth. Mol Oncol. 8:93–104. 2014. View Article : Google Scholar : PubMed/NCBI
19	Denoyelle C, Lambert B, Meryet-Figuiere M, Vigneron N, Brotin E, Lecerf C, Abeilard E, Giffard F, Louis MH, Gauduchon P, et al: miR-491-5p-induced apoptosis in ovarian carcinoma depends on the direct inhibition of both BCL-XL and EGFR leading to BIM activation. Cell Death Dis. 5:e14452014. View Article : Google Scholar : PubMed/NCBI
20	Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H and Yu H: Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 6:391–401. 2014.PubMed/NCBI
21	Guo R, Wang Y, Shi WY, Liu B, Hou SQ and Liu L: MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway. Molecules. 17:14733–14747. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zhou Y, Li Y, Ye J, Jiang R, Yan H, Yang X, Liu Q and Zhang J: MicroRNA-491 is involved in metastasis of hepatocellular carcinoma by inhibitions of matrix metalloproteinase and epithelial to mesenchymal transition. Liver Int. 33:1271–1280. 2013. View Article : Google Scholar : PubMed/NCBI
23	Hu J, Van den Steen PE, Sang QX and Opdenakker G: Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov. 6:480–498. 2007. View Article : Google Scholar : PubMed/NCBI
24	Roy R, Yang J and Moses MA: Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol. 27:5287–5297. 2009. View Article : Google Scholar : PubMed/NCBI
25	Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, van Duijn W, van den Berg M, van Hogezand RA, Lamers CB and Verspaget HW: Expression of matrix metalloproteinases-2 and −9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis. 37:584–592. 2005. View Article : Google Scholar : PubMed/NCBI
26	Ordás I, Eckmann L, Talamini M, Baumgart DC and Sandborn WJ: Ulcerative colitis. Lancet. 380:1606–1619. 2012. View Article : Google Scholar : PubMed/NCBI
27	Ben David D, Reznick AZ, Srouji S and Livne E: Exposure to pro-inflammatory cytokines upregulates MMP-9 synthesis by mesenchymal stem cells-derived osteoprogenitors. Histochem Cell Biol. 129:589–597. 2008. View Article : Google Scholar : PubMed/NCBI
28	Rodriguez D, Morrison CJ and Overall CM: Matrix metalloproteinases: What do they not do? New substrates and biological roles identified by murine models and proteomics. Biochim Biophys Acta. 1803:39–54. 2010. View Article : Google Scholar : PubMed/NCBI
29	Ram M, Sherer Y and Shoenfeld Y: Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol. 26:299–307. 2006. View Article : Google Scholar : PubMed/NCBI
30	Grossmann J: Molecular mechanisms of ‘detachment-induced apoptosis-Anoikis’. Apoptosis. 7:247–260. 2002. View Article : Google Scholar : PubMed/NCBI
31	Delclaux C, Delacourt C, D'Ortho MP, Boyer V, Lafuma C and Harf A: Role of gelatinase B and elastase in human polymorphonuclear neutrophil migration across basement membrane. Am J Respir Cell Mol Biol. 14:288–295. 1996. View Article : Google Scholar : PubMed/NCBI
32	Mast BA and Schultz GS: Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen. 4:411–420. 1996. View Article : Google Scholar : PubMed/NCBI
33	Jain A and Bahuguna R: Role of matrix metalloproteinases in dental caries, pulp and periapical inflammation: An overview. J Oral Biol Craniofac Res. 5:212–218. 2015. View Article : Google Scholar : PubMed/NCBI
34	Latifa K, Sondess S, Hajer G, Manel BH, Souhir K, Nadia B, Abir J, Salima F and Abdelhedi M: Evaluation of physiological risk factors, oxidant-antioxidant imbalance, proteolytic and genetic variations of matrix metalloproteinase-9 in patients with pressure ulcer. Sci Rep. 6:293712016. View Article : Google Scholar : PubMed/NCBI
35	Tian X and Zhang X: A single nucleotide polymorphism (rs1056629) in 3′-UTR of MMP-9 is responsible for a decreased risk of metastatic osteosarcoma by compromising its interaction with microRNA-491-5p. Cell Physiol Biochem. 38:1415–1424. 2016. View Article : Google Scholar : PubMed/NCBI